Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

This is a prospective validation study, multicenter, open-label, single-arm study, evaluating the concordance between capillary microsampling (using the VAMS Mitra device) and venous sampling in patients undergoing CDK4/6 therapy.

Key facts

Study ID

NCT07491380

Run by

Institut Curie

People needed

90

Starts

2026-06-23

Expected to finish

2029-01-23

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (≥ 18 years) with breast cancer.
• Patients currently receiving ribociclib, abemaciclib, or palbociclib.
• Patients capable of performing capillary sampling (with or without assistance).
• Patient information and signing of informed consent.
• Patient ability to comply with protocol requirements.
• Patients covered by a health insurance system.

You may not qualify if…

• Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.
• Persons deprived of their liberty or under guardianship.

Where it is running

• Institut Curie Paris — Paris, France (enrolling)
• Institut Curie — Saint-Cloud, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.